← Back to Search

Convulsive Therapy

Convulsive Therapies for Bipolar Disorder (CORRECT-BD Trial)

Vancouver, Canada
N/A
Waitlist Available
Led By Daniel Blumberger, MD, MSc
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must be voluntary and competent to consent to treatment and research procedures according to ECT/MST attending psychiatrist
Patients must be 18 years of age or older
Must not have
Patients must not have any significant neurological disorder or condition likely to be associated with increased intracranial pressure or a space occupying brain lesion, e.g., cerebral aneurysm
Patients must not have a concomitant major unstable medical illness
Timeline
Screening 3 weeks
Treatment Varies
Follow Up greater than 8 treatments (2.5 weeks)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether magnetic seizure therapy is more effective and tolerable than electroconvulsive therapy for treating bipolar disorder.

See full description
Who is the study for?
This trial is for adults over 18 with non-psychotic Bipolar Disorder (Type I or II) who have a significant level of depression. They must be able to consent, follow the treatment schedule, and keep their current antidepressant constant. Exclusions include major unstable illnesses, pregnancy intention during the study, primary psychotic disorders, recent substance abuse, certain neurological conditions or implants, high doses of benzodiazepines or anticonvulsants.Check my eligibility
What is being tested?
The trial compares Magnetic Seizure Therapy (MST) with Electroconvulsive Therapy (ECT) in treating bipolar depression. It aims to find out if MST can be an effective alternative to ECT by providing better response rates in patients resistant to other treatments.See study design
What are the potential side effects?
While not explicitly listed here, side effects may include memory issues and confusion typically associated with ECT. MST might present similar risks due to its nature as a convulsive therapy but is being studied for potentially fewer cognitive side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am willing and able to agree to treatment and research procedures.
 show original
Select...
I am 18 years old or older.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any major brain disorders or conditions that could increase pressure inside my skull.
 show original
Select...
I do not have any major unstable illnesses.
 show original
Select...
I don't take more than 2 mg/day of lorazepam or any similar medication.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~greater than 8 treatments (2.5 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and greater than 8 treatments (2.5 weeks) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cognitive adverse effects as indexed by the Autobiographical Memory Test (AMT)
Remission (score </= 10) on the Hamilton Rating Scale for Depression - 24 (HRSD-24)
Secondary study objectives
Improvement in symptom severity of Suicidal Ideation as measured by the Scale for Suicidal Ideation (SSI)
Number of self-reported and clinical-reported adverse events

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Magnetic Seizure Therapy (MST)Experimental Treatment1 Intervention
MST treatments will be administered using the MagPro MST with Cool TwinCoil.
Group II: Electroconvulsive Therapy (ECT)Active Control1 Intervention
ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnetic Seizure Therapy (MST)
2018
N/A
~190

Find a Location

Closest Location:UBC Hospital, University of British Columbia (UBC)· Vancouver, Canada

Who is running the clinical trial?

Centre for Addiction and Mental HealthLead Sponsor
386 Previous Clinical Trials
84,144 Total Patients Enrolled
17 Trials studying Bipolar Disorder
1,512 Patients Enrolled for Bipolar Disorder
University of British ColumbiaOTHER
1,501 Previous Clinical Trials
2,528,147 Total Patients Enrolled
16 Trials studying Bipolar Disorder
1,809 Patients Enrolled for Bipolar Disorder
Brain CanadaOTHER
21 Previous Clinical Trials
5,976 Total Patients Enrolled
2 Trials studying Bipolar Disorder
349 Patients Enrolled for Bipolar Disorder
Ontario Shores Centre for Mental Health SciencesOTHER
14 Previous Clinical Trials
2,311 Total Patients Enrolled
2 Trials studying Bipolar Disorder
346 Patients Enrolled for Bipolar Disorder
Daniel Blumberger, MD, MScPrincipal InvestigatorCentre for Addiction and Mental Health
4 Previous Clinical Trials
744 Total Patients Enrolled
1 Trials studying Bipolar Disorder
106 Patients Enrolled for Bipolar Disorder

Media Library

ECT (Convulsive Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03641300 — N/A
Bipolar Disorder Research Study Groups: Electroconvulsive Therapy (ECT), Magnetic Seizure Therapy (MST)
Bipolar Disorder Clinical Trial 2023: ECT Highlights & Side Effects. Trial Name: NCT03641300 — N/A
ECT (Convulsive Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03641300 — N/A
~10 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top